The BET1 Knockout HEK293T Polyclonal Cells represent a CRISPR/Cas9-engineered polyclonal knockout cell population designed for the study of secretory pathway trafficking. This product comprises HEK293T cells with targeted disruption of the BET1 gene, achieved through CRISPR/Cas9-mediated gene editing, yielding a diverse loss-of-function model. The polyclonal nature ensures heterogeneous gene knockout events, offering a robust platform for functional analyses of BET1 in membrane transport.
HEK293T is a human embryonic kidney epithelial cell line that constitutively expresses the SV40 large T-antigen, enhancing plasmid transfection efficiency and protein expression. This derivative of the HEK293 cell line is widely utilized for its high transfection capability and robust secretory pathway, making it an ideal host for investigating ER-to-Golgi transport and protein secretion mechanisms.
The BET1 gene encodes a SNARE protein essential for the tethering and fusion of COPII vesicles with the cis-Golgi membrane. BET1 directly interacts with syntaxin-5 (STX5), GOSR2, SEC22B, and BNIP1 to form a functional SNARE complex that drives anterograde transport from the endoplasmic reticulum. Knockout of BET1 disrupts this complex, blocking cargo delivery to the Golgi, inducing ER stress, and impairing protein secretion. Upstream, BET1 function is regulated by ER stress sensors and COPII coat assembly; downstream, it is critical for the proper localization and secretion of Golgi-resident enzymes, cell surface receptors, and secretory proteins.
In the HEK293T background, loss of BET1 severely compromises the cell line??s innate capacity for high-level protein secretion. This knockout model provides a powerful system to examine how impaired ER-to-Golgi trafficking affects cellular homeostasis, glycosylation pathways, and stress responses. The polyclonal knockout population captures a spectrum of genetic disruptions, facilitating studies of phenotype heterogeneity and enabling genetic or pharmacological rescue experiments. Researchers can exploit this model to dissect the effects of BET1 deficiency on cargo-specific trafficking and downstream signaling.
These BET1 knockout HEK293T polyclonal cells are suitable for a wide array of research applications, including mechanistic dissection of ER-to-Golgi transport, characterization of SNARE complex assembly, and modeling of diseases rooted in secretory dysfunction, such as congenital disorders of glycosylation and cancer metastasis. Typical assays include western blotting for BET1 and cargo proteins, immunofluorescence microscopy of ER and Golgi markers, secretion assays for model proteins, RT-qPCR for ER stress markers, and co-immunoprecipitation to probe SNARE interactions. For additional information or to place an order, contact Ascent Research.
